Fate Therapeutics Licenses Stem-Cell Modulators for Bone Regeneration from UCLA | GenomeWeb

Stem cell therapeutics company Fate Therapeutics said today that it has acquired from the University of California, Los Angeles, exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation.

With the deal, UCLA becomes at least the eighth university or research institution from which Fate has licensed IP to bolster its portfolio of stem-cell modulators — small molecules and biologics to modulate cells for therapeutic purposes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.